EMA opinion on the presence of dangerous impurities in sartan medicines

The EMA launched a review of sartan medicines in 2018 after probable carcinogenic impurities were discovered.
The EMA launched a review of sartan medicines in 2018 after probable carcinogenic impurities were discovered.